121 related articles for article (PubMed ID: 12544409)
1. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Litalien C; Faye A; Compagnucci A; Giaquinto C; Harper L; Gibb DM; Jacqz-Aigrain E;
Pediatr Infect Dis J; 2003 Jan; 22(1):48-55. PubMed ID: 12544409
[TBL] [Abstract][Full Text] [Related]
2. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Payen S; Faye A; Compagnucci A; Giaquinto C; Gibbs D; Gomeni R; Bressolle F; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2005 Feb; 49(2):525-35. PubMed ID: 15673728
[TBL] [Abstract][Full Text] [Related]
3. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.
Capparelli EV; Sullivan JL; Mofenson L; Smith E; Graham B; Britto P; Becker MI; Holland D; Connor JD; Luzuriaga K;
Pediatr Infect Dis J; 2001 Aug; 20(8):746-51. PubMed ID: 11734735
[TBL] [Abstract][Full Text] [Related]
6. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.
Read JS; Best BM; Stek AM; Hu C; Capparelli EV; Holland DT; Burchett SK; Smith ME; Sheeran EC; Shearer WT; Febo I; Mirochnick M
HIV Med; 2008 Nov; 9(10):875-82. PubMed ID: 18795962
[TBL] [Abstract][Full Text] [Related]
8. The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.
Sheehan NL; van Heeswijk RP; Foster BC; Akhtar H; Singhal N; Seguin I; DelBalso L; Bourbeau M; Chauhan BM; Boulassel MR; Burger DM; Lalonde RG; Cameron DW
Molecules; 2012 Jan; 17(1):688-702. PubMed ID: 22241465
[TBL] [Abstract][Full Text] [Related]
9. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Khaliq Y; Gallicano K; Seguin I; Fyke K; Carignan G; Bulman D; Badley A; Cameron DW
Br J Clin Pharmacol; 2000 Aug; 50(2):108-15. PubMed ID: 10930962
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
Regazzi M; Maserati R; Villani P; Cusato M; Zucchi P; Briganti E; Roda R; Sacchelli L; Gatti F; Delle Foglie P; Nardini G; Fabris P; Mori F; Castelli P; Testa L
Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.
Fletcher CV; Brundage RC; Fenton T; Alvero CG; Powell C; Mofenson LM; Spector SA
Clin Pharmacol Ther; 2008 Feb; 83(2):300-6. PubMed ID: 17609682
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Regazzi MB; Villani P; Maserati R; Seminari E; Pan A; LoCaputo F; Gambarana E; Fiocchi C
J Antimicrob Chemother; 2000 Mar; 45(3):343-7. PubMed ID: 10702554
[TBL] [Abstract][Full Text] [Related]
15. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
17. Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Rongkavilit C; van Heeswijk RP; Limpongsanurak S; Thaithumyanon P; Boonrod C; Hassink EA; Srigritsanapol A; Chuenyam T; Ubolyam S; Hoetelmans RM; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):455-63. PubMed ID: 11981361
[TBL] [Abstract][Full Text] [Related]
18. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
Bergshoeff AS; Wolfs TF; Geelen SP; Burger DM
Ann Pharmacother; 2003 Apr; 37(4):521-5. PubMed ID: 12659608
[TBL] [Abstract][Full Text] [Related]
20. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
Zhang KE; Wu E; Patick AK; Kerr B; Zorbas M; Lankford A; Kobayashi T; Maeda Y; Shetty B; Webber S
Antimicrob Agents Chemother; 2001 Apr; 45(4):1086-93. PubMed ID: 11257019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
